Live Breaking News & Updates on Anthony Sung

Stay updated with breaking news from Anthony sung. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

COVID fighter? Probiotics could treat unvaccinated exposed to deadly infection, Duke researchers say

The randomized, placebo-controlled study led by Duke Health researchers suggests that probiotics could be a relatively simple and inexpensive approach to treating people after a COVID exposure. ....

United States , Zenie Ramirez , Yi Ren , Neerajk Surana , Hilarym Miller , Lauren Bohannon , Ernaya Johnson , Paul Wischmeyer , Amy Bush , Meaganv Lew , Alessandro Racioppi , Tessam Andermann , Claudiae Pamanes , Helen Tang , David Jensen , Anne Britt , Aaront Zhao , Alexandra Artica , Juliaa Messina , Centers For Disease , Duke Health , Duke Microbiome Center , Department Of Medicine , Department Of Anesthesiology , Disease Control , Anthony Sung ,

Probiotics reduce COVID symptoms and delay disease among unvaccinated

Probiotics reduce COVID symptoms and delay disease among unvaccinated
medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.

United States , Paule Wischmeyer , Helen Tang , Paul Wischmeyer , Centers For Disease , Duke Health , Duke Department Of Anesthesiology , Duke Department Of Medicine , Clinical Nutrition , Disease Control , Anthony Sung , Placebo Controlled Randomized ,

More Options For People With Blood Cancers

Innovations in using bone marrow from donors who aren’t a perfect match and in using cord blood have made stem cell transplants for blood cancers available to more patients. ....

Edwin Alyea , Joanne Kurtzberg , Mitchell Horwitz , Mary Russell Roberson , Jeromes Harris , Nelson Chao , Duke Cancer Institute , Division Of Cell Therapy , Drug Administration , Duke Cancer , Larger Pool , Distinguished Professor , Cell Therapy , Anthony Sung , Stem Cell Transplant , Russell Roberson ,

FDA Panel: Concerns Over PI3K Inhibitors in Blood Cancers

An FDA advisory panel voted in favor of using randomized trials of PI3K drugs instead of single-arm studies in blood cancer studies, because of concerns about toxicities in this class of drugs. ....

United States , Nicole Gormley , Richard Pazdur , Jorge Garcia , Gita Thanarajasingam , Jorge Nieva , Los Angeles , Oncologic Drugs Advisory Committee , Drug Administration , University Of Southern California , Duke University , Case Western Reserve University School Of Medicine , Anthony Sung , Case Western Reserve University School , Mayo Clinic , Several Years , Southern California , Patient Safety , Us Food And Drug Administration , Nited States Food And Drug Administration , Hematologic Malignancies , Alignant Neoplasia , Chronic Lymphocytic Leukemia , Follicular Lymphoma , Non Hodgkins Lymphoma , Drug Induced Toxicity ,

FDA Panel Splits on Anti-PD-1 Monotherapy in HCC

email article
A pair of PD-1 immunotherapies used in advanced hepatocellular carcinoma (HCC) met sharply different receptions from FDA advisers reviewing accelerated approvals that failed to show benefit in confirmatory trials.
In considering the two agents for previously treated HCC, the Oncologic Drugs Advisory Committee (ODAC) on Thursday unanimously recommended that FDA maintain its accelerated approval of pembrolizumab (Keytruda), by a vote of 8-0, but split over nivolumab (Opdivo), with a 5-4 vote in favor of revoking the indication.
The divided decision largely stemmed from whether ongoing trials would offer new evidence to support the indications. ODAC members took a wait-and-see approach with pembrolizumab given the imminent readout of KEYNOTE-394, a placebo-controlled second-line trial being conducted in Asia. But with nivolumab, they remained unconvinced that any ongoing trial from drugmaker Bristol Myers Squibb (BMS) would adequately provide insig ....

North Carolina , United States , New Haven , Yale University , Pamela Kunz , Philip Hoffman , Richard Pazdur , Bristol Myers Squibb , Mark Lewis , Oncologic Drugs Advisory Committee , University Of Colorado , University Of Chicago , Yale University School Of Medicine , Office Of Oncologic Diseases , Yale University School , Intermountain Healthcare , Christopher Lieu , Such Luck , Anthony Sung , Duke Adult Blood , Marrow Transplant Clinic , Oncologic Diseases , Drug Evaluation , Managing Editor , Medpage Today , வடக்கு கரோலினா ,